Insmed Incorporated Overview
Pro stress-test →Insmed develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company is at a critical inflection point, driven by its flagship product ARIKAYCE and the monumental European approval of BRINSUPRI (brensocatib) in November 2025, a first-in-class therapy for non-cystic fibrosis bronchiectasis.
Strategic Profile
Pro stress-test →Insmed's business model is centered on the high-value, specialty drug market, where a premium price is justified by treating rare diseases with few or no alternative therapies. The company leverages a focused commercial strategy for rare pulmonary and systemic diseases with strong clinical data and regulatory momentum, positioning it for accelerated revenue growth through newly approved and late-stage pipeline assets.
Competitive Landscape
Pro stress-test →Key competitors include Ardelyx, Arrowhead Pharmaceuticals, Rallybio, Corcept Therapeutics, and AM-Pharma. Insmed differentiates through focused expertise in rare pulmonary diseases, proprietary specialty formulations (inhaled/inhalation), and first-mover advantages in niche indications with limited therapeutic alternatives.
Industry Context
Insmed Incorporated operates in Biopharmaceutical/Specialty Pharma - Rare Diseases.
Key facts
Founded: 1988 · Headquarters: Bridgewater, New Jersey · Employees: 1,556 · Revenue: $447M · Market cap: $31.9B